Designing drugs with the optimal combination of GLP-1R and GCGR activation is important and may confer greater benefits in reversing diabetes than GLP-1R activation alone, as demonstrated recently [39,40,41,42]. This evidence concerns the gene GCGR and diabetes mellitus.